Charles River Laboratories (CRL) has completed the acquisition of the CRO services division of Galapagos NV, which includes both Argenta and BioFocus, for$179 million in cash. The acquisition, along with CRL’s current capabilities, adds integrated in vitro and in vivo capabilities from target discovery through preclinical development.   Argenta and BioFocus, located in the UK and the Netherlands, provide drug discovery services from target discovery through the delivery of clinic-ready candidate...